NCT03332485已完成2 期
A Randomized, Investigator- and Colonoscopist-blinded, Phase 2 Study of the Efficacy and Safety of ECP (Polyethylene Glycol 3350 [PEG 3350]) Colon Prep Kit Compared With MoviPrep® Split-dose for Colonoscopy Preparation
Sebela Pharmaceuticals Development LLC8 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年11月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 8
- 主要终点
- Proportion of subjects with successful bowel cleansing defined as centrally read 4 point modified Aronchick Scale (1=Inadequate, 2=Fair, 3=Good, 4=Excellent) score of either good or excellent.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of ECP (PEG 3350) Colon Prep Kit compared with MoviPrep split-dose as a colon-cleansing preparation for colonoscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Scheduled to undergo a medically indicated colonoscopy for colorectal cancer screening or surveillance for colorectal cancer
- •Females must be non-lactating and have a negative pregnancy test if of child bearing potential
- •Ability and willingness of subject to participate fully in all aspects of this clinical trial
- •Written informed consent
排除标准
- •Known or suspected clinically significant intestinal stricture of any etiology
- •History of diabetes mellitus, controlled with insulin
- •Taking insulin by injection
- •Pregnant or lactating
- •Renal insufficiency, hypokalemia, hyperkalemia, chronic liver disease or arrhythmic disorder
- •Chronic heart failure or recent (within 90 days of screening) acute heart failure
- •Receiving warfarin, heparin, clopidogrel, Pradaxa®, Xarelto®, Effient® or other blood thinning agents
- •Short bowel syndrome
- •Known diagnosis of Crohn's disease or ulcerative colitis, exclusionary only if subject has a history of any bowel resection, has suspected active inflammation, has symptoms suggestive of obstruction or a known bowel stricture
- •Severe psychological disease causing functional impairment limiting capacity to complete the preparation
- •Impaired consciousness increasing the risk of aspiration
- •Used narcotics/opiates within the 14 days prior to the colonoscopy
- •Used an anti-diarrheal within the 14 days prior to the colonoscopy procedure
- •Uses drugs of abuse including abused prescription medication
- •Used iron supplements within 14 days of the colonoscopy procedure
- •History of gastrointestinal surgery other than appendectomy or cholecystectomy
- •Diagnosis of gastroparesis or ileus
- •Symptoms of chronic constipation defined as fewer than 3 bowel movements per week on average over the previous 3 months
- •History of a failed bowel preparation, defined as either requiring an enema the day of the colonoscopy or needing to have the colonoscopy repeated
- •CTCAE grade 1 sodium, potassium or magnesium at screening
- •Clinically significant abnormalities (ketones, protein, glucose) at screening urinalysis, in the opinion of the investigator
- •Any known allergies to any of the ingredients or ECP Colon Prep Kit (including coconut) or the active comparator
- •Unable or unwilling to consume all components of the study drug including aversions to or adverse events from flavoring
- •Received any investigational therapy within 30 days of initiation of study drug
- •Serious underlying disease that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study
- •Requirement to use chromoendoscopy during the procedure for the purpose of surveillance for colorectal dysplasia or cancer in subjects with inflammatory bowel disease
研究组 & 干预措施
ECP Colon Prep Kit
Experimental
干预措施: ECP Colon Prep Kit (Drug)
MoviPrep®
Active Comparator
干预措施: MoviPrep® (Drug)
结局指标
主要结局
Proportion of subjects with successful bowel cleansing defined as centrally read 4 point modified Aronchick Scale (1=Inadequate, 2=Fair, 3=Good, 4=Excellent) score of either good or excellent.
时间窗: 24-hour period, beginning the day prior to the procedure and through the morning of the colonoscopy procedure.
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
4 期
Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.Colonoscopy PreparationNCT02073552Fundación Canaria Rafael Clavijo para la Investigación Biomédica472
已完成
4 期
Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical NutritionColonoscopyNCT02714296Nutricia Advanced150
进行中（未招募）
不适用
Impact of Protect Your Colon™ on CRC ScreeningColorectal Cancer ScreeningNCT05929820Cedars-Sinai Medical Center184
已完成
不适用
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and ProcedureBowel DiseasesNCT00885235Medtronic - MITG40
已完成
4 期
Sodium Picosulphate/Magnesium Citrate and Low-volume PEG -Ascorbic Acid as Preparation for ColonoscopyColon Cleansing for ColonoscopyNCT01603654ASST Fatebenefratelli Sacco300